Evidence map›Paper›PMID 39060206›Full record

ArticleAcademic radiology2024

Special Report on the Consensus QIBA Profile for Objective Analytical Validation of Non-calcified and High-risk Plaque and Other Biomarkers using Computed Tomography Angiography.

Andrew J Buckler, Suhny Abbara, Matthew J Budoff, John Jeffrey Carr, Carlo N De Cecco, J Kevin DeMarco, Maros Ferencik, Gemma A Figtree, Ichiro Ikuta, Márton Kolossváry and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Academic radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Andrew J BucklerBBMSC, Boston, Massachusetts, USA (A.J.B.). Electronic address: andrew.buckler@bbmsc.com.
Suhny AbbaraUT Southwestern, Dallas, Texas, USA (S.A.).
Matthew J BudoffDepartment of Medicine, Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, USA (M.J.B.).
John Jeffrey CarrVanderbilt University Medical Center, Nashville, Tennessee, USA (J.J.C.).
Carlo N De CeccoEmory University, Atlanta, Georgia, USA (C.N.D.C., M.C.W.).
J Kevin DeMarcoWalter Reed National Military Medical Center and Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA (J.K.D.).
Maros FerencikOregon Health & Science University, Portland, Oregon, USA (M.F.).
Gemma A FigtreeDepartment of Cardiology, Royal North Shore Hospital, St Leonards, NSW, Australia (G.A.F.); Cardiovascular Discovery Group, Kolling Institute of Medical Research, St Leonards, Australia (G.A.F.); Faculty of Medicine & Health, University of Sydney, Camperdown, Royal North Shore Hospital, St Leonards, NSW, Australia (G.A.F.).
Ichiro IkutaMayo Clinic Arizona, Phoenix, Arizona, USA (I.I.).
Márton KolossváryGottsegen National Cardiovascular Center, Budapest, Hungary (M.K.); Physiological Controls Research Center, University Research and Innovation Center, Óbuda University, Budapest, Hungary (M.K.).
Mathis KonradDepartment of Diagnostic and Interventional Radiology, Heidelberg University Hospital, Heidelberg, Germany (M.K.).
Brajesh K LalDepartment of Vascular Surgery, University of Maryland, Baltimore, Maryland, USA (B.K.L.); Vascular Service, VA Medical Center, Baltimore, Maryland, USA (B.K.L.).
Hugo MarquesHospital da Luz, Imaging Department - Católica Medical School, Lisboa, Portugal (H.M.).
Alastair J MossDepartment of Cardiovascular Sciences and National Institute for Health Research Leicester Biomedical Research Centre, University of Leicester, Leicester, UK (A.J.M.).
Nancy A ObuchowskiQuantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio, USA (N.A.O.).
Edwin J R van BeekEdinburgh Imaging, University of Edinburgh, Scotland (E.J.R.V.B.).
Renu VirmaniCV Path Institute, Gaithersburg, Maryland, USA (R.V.).
Michelle C WilliamsEmory University, Atlanta, Georgia, USA (C.N.D.C., M.C.W.); Centre for Cardiovascular Science, University of Edinburgh, Scotland (M.C.W.).
Luca SabaUniversity of Cagliari, Sardinia, Italy (L.S.).
U Joseph SchoepfMedical University of South Carolina, Charleston, South Carolina, USA (U.J.S.).

Funding

NHLBI NIH HHS HHSN268201500021CNIBIB NIH HHS HHSN268201000050CNIBIB NIH HHS HHSN268201300071C
6 · The paper itself

Abstract

RATIONALE AND

objectivesEvidence is building in support of the clinical utility of atherosclerotic plaque imaging by computed tomography angiography (CTA). There is increasing organized activity to embrace non-calcified plaque (NCP) as a formally defined biomarker for clinical trials, and high-risk plaque (HRP) for clinical care, as the most relevant measures for the field to advance and worthy of community efforts to validate. Yet the ability to assess the quantitative performance of any given specific solution to make these measurements or classifications is not available. Vendors use differing definitions, assessment metrics, and validation data sets to describe their offerings without clinician users having the capability to make objective assessments of accuracy and precision and how this affects diagnostic confidence. MATERIALS AND

methodsThe QIBA Profile for Atherosclerosis Biomarkers by CTA was created by the Quantitative Imaging Biomarkers Alliance (QIBA) to improve objectivity and decrease the variability of noninvasive plaque phenotyping. The Profile provides claims on the accuracy and precision of plaque measures individually and when combined.

resultsIndividual plaque morphology measurements are evaluated in terms of bias (accuracy), slope (consistency of the bias across the measurement range, needed for measurements of change), and variability. The multiparametric plaque stability phenotype is evaluated in terms of agreement with expert pathologists. The Profile is intended for a broad audience, including those engaged in discovery science, clinical trials, and patient care.

conclusionThis report provides a rationale and overview of the Profile claims and how to comply with the Profile in research and clinical practice. SUMMARY STATEMENT: This article summarizes objective means to validate the analytical performance of non-calcified plaque (NCP), other emerging plaque morphology measurements, and multiparametric histology-defined high-risk plaque (HRP), as outlined in the QIBA Profile for Atherosclerosis Biomarkers by CTA.

Indexed as

BiomarkersComputed Tomography AngiographyPlaque, AtheroscleroticConsensusHumansReproducibility of ResultsBiomarkersAtherosclerosisGuidelinesHigh-risk plaqueMultiparametric biomarkerNon-calcified plaquePlaque imagingProfileQuantitative imaging biomarkers

Identifiers

PMID39060206
PMCPMC11606787

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.